The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes, a ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

DD01 is a liver-targeted, long-acting, dual GLP-1/glucagon receptor ... for DD01 lies in its dual pathway mechanism of action. Unlike single and dual agonists, which act only through the incretin ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

“While they act through different biochemical pathways, both GLP-1 agonists and SGLT2 inhibitors have been shown to decrease the risk of cardiovascular disease. They both likely accomplish this by ...